56824-90-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloro-8-fluoroquinoline-3-carboxylate is used as a key intermediate for the synthesis of [[(alkylsulfonyl)phenoxy]phenyl]quinolines. These quinoline derivatives exhibit good binding affinity for the liver X receptor beta (LXRβ), which plays a crucial role in regulating lipid and glucose metabolism, inflammation, and cellular proliferation. The moderate binding selectivity over liver X receptor alpha (LXRα) makes these compounds potentially useful in the treatment of various diseases, including metabolic disorders, atherosclerosis, and neurodegenerative diseases.
Additionally, the compound may be utilized in other industries for different applications, such as:
1. Chemical Research and Development:
Ethyl 4-chloro-8-fluoroquinoline-3-carboxylate can be used as a starting material or building block in the synthesis of novel quinoline-based compounds with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.
2. Drug Design and Optimization:
Ethyl 4-chloro-8-fluoroquinoline-3-carboxylate can be employed in the design and optimization of new drug candidates targeting LXRβ, which may lead to the development of more effective and selective therapies for diseases associated with this receptor.
3. Academic and Industrial Research:
Ethyl 4-chloro-8-fluoroquinoline-3-carboxylate can be used in research laboratories for studying the structure-activity relationships of quinoline-based compounds and exploring their potential applications in various fields.

InChI:InChI=1/C12H9ClFNO2/c1-2-17-12(16)8-6-15-11-7(10(8)13)4-3-5-9(11)14/h3-6H,2H2,1H3

Upstream product

• 63010-69-5 ethyl 8-fluoro-4-hydroxy-3-quinolinecarboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 63010-68-4 diethyl [(2-fluoroanilino)methylidene]malonate 
• 348-54-9 2-Fluoroaniline 

Downstream Products

• 702706-01-2 3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid 
• 1207711-34-9 C₁₈H₁₄FNO₃ 

Relevant academic research and scientific papers

Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies

In present study a series of triazolopyrimidine-quinoline and cyanopyridine-quinoline hybrids were designed, synthesized and evaluated as acetylcholinesterase inhibitors (AChEIs). Molecular docking and scoring was utilized for the design of inhibitors. The molecules were synthesized via an easily accessible, convergent synthetic route. Three triazolopyrimidine based compounds showed nanomolar activity towards acetylcholinesterase. Among them, Ethyl 6-fluoro-4-(4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl)quinoline-3-carboxylate (10d), strongly inhibited AChE with IC50 value of 42 nM. Furthermore compound 10d was identified as most promising compound with 12 fold selectivity against butyrylcholinesterase (BuChE). This compound displayed a composed multitargeted profile with promising inhibition of self-induced and AChE - induced Aβ aggregation and antioxidant activity.

Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low blood-brain penetration

A series of quinoline-3-carboxamide containing sulfones was prepared and found to have good binding affinity for LXRβ and moderate binding selectivity over LXRα. The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRβ over LXRα (LXRβ IC50 = 16 nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the LXRα Gal4 functional assay, and low blood-brain barrier penetration in rat.

QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION PROCESS FOR THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided is a quinoline derivative represented by the following Formula (1) for use in treating a caspase- mediated disease by inhibition of caspase-3 activity. Further provided are a method for preparing the quinoline derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS

There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15- lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.